YOLFTbeta
Aton

Aton

ALTAO · PA · Healthcare / Biotechnology

0.006EUR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.006
Open0.0062
Day Range0.0058 – 0.0066
52-Week Range0.005 – 0.029
Volume21.58M
Market Cap14.86M
P/E (TTM)0.00
Forward P/E7.30
EPS0.00
Dividend Yield0.00%
Beta0.72
50-Day Avg0.0135
200-Day Avg0.0101

About

Aton operates as a bioscience company in France. It engages in drug development, preclinical and clinical services, production of monoclonal antibodies, laboratory equipment production, and designing and manufacturing of medical devices, as well as provision of human tissues. The company also offers medical devices for surgeons, powered by Stemcis. The company was founded in 1998 and is headquartered in Strasbourg, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Hadrien Lanvin
  • Employees13
  • Headquarters850 Boulevard Sébastien Brant, Strasbourg, France, 67400, France
  • Websitehttps://www.aton-group.com

Leadership

  • Ms. Ayikoele AtayiGM & Chair of the Board of Directors
  • Mr. Hadrien LanvinDeputy CEO & Director

Financials

Income Statement

Currency: EUR2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.17M3.73M2.25M4.58M5.62M5.55M4.63M3.61M1.88M76.73K234.93K150.62K147.13K1.56K383.80K614.00K661.00K
Growth (%)--10.41%-39.63%+102.97%+22.83%-1.30%-16.47%-22.20%-47.86%-95.92%+206.17%-35.89%-2.32%-98.94%+24502.63%+59.98%+7.65%
Cost of Revenue753.00K698.00K3.40M4.14M3.63M4.43M4.04M1.02M4.46M31.59K1.25K967.13K386.66K530.18K123.00K170.00K
Gross Profit3.42M3.04M-1.15M439.00K1.99M1.12M591.00K2.59M-2.58M45.14K233.68K150.53K140.00K-385.10K-146.38K491.00K491.00K
Gross Margin81.94%81.31%-50.91%9.59%35.38%20.15%12.75%71.82%-137.39%58.83%99.47%99.94%95.15%-24685.83%-38.14%79.97%74.28%
Operating Expense8.35M7.90M2.08M4.16M4.40M4.74M5.00M6.91M4.79M7.68M1.59M467.63K260.49K205.05K606.80K1.87M1.29M
Operating Income-4.93M-4.86M-3.23M-3.72M-2.41M-3.62M-4.41M-4.32M-7.38M-7.64M-1.36M-317.11K-120.49K-590.14K-753.18K-1.38M-800.00K
Operating Margin-118.33%-130.23%-143.33%-81.30%-42.83%-65.31%-95.23%-119.80%-392.39%-9954.19%-579.15%-210.53%-81.89%-37829.81%-196.24%-224.43%-121.03%
EBITDA-3.99M-3.78M-2.66M-3.18M-1.69M-3.03M-3.61M-3.01M-7.14M-7.39M-1.27M-268.61K-113.36K-507.75K-450.67K-22.00K-104.00K
EBITDA Margin-95.66%-101.29%-118.00%-69.50%-30.02%-54.53%-77.97%-83.36%-380.05%-9636.87%-539.97%-178.33%-77.05%-32547.95%-117.42%-3.58%-15.73%
Net Income-4.20M-4.56M-2.29M-2.45M-1.79M-2.92M-4.38M-5.26M-7.96M-7.53M-923.08K-329.10K296.76K-563.57K-18.85M-1.10M-962.00K
Net Income Margin-100.65%-122.03%-101.64%-53.62%-31.80%-52.62%-94.39%-145.78%-423.24%-9811.40%-392.92%-218.49%201.70%-36126.28%-4910.49%-179.32%-145.54%
R&D-----1.55M2.55M3.37M7.00K-----66.00K1.00K0
R&D as % of Total Revenue-----27.90%54.99%93.37%0.37%-----17.20%0.16%0.00%
Interest Expense104.00K141.00K-12.00K2.00K1.00K30.00K11.00K4.00K200.02K187.60K2.42K21.68K56.57K132.99K256.00K56.00K
Interest Expense % of Total Revenue2.49%3.78%-0.26%0.04%0.02%0.65%0.31%0.21%260.67%79.85%1.60%14.73%3626.28%34.65%41.69%8.47%

Balance Sheet

Currency: EUR2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets8.34M6.97M5.84M7.08M7.92M16.95M21.30M16.18M13.97M3.99M5.91M6.42M13.15M15.20M1.03M6.45M5.81M
Total Liabilities5.68M7.29M6.76M5.70M5.47M5.94M5.33M5.30M4.81M2.71M681.70K1.52M3.72M4.97M5.72M5.27M5.42M
Total Equity2.66M-316.00K-915.00K1.35M2.41M10.97M15.90M10.80M9.16M1.28M5.23M4.90M9.43M10.23M-4.69M791.00K37.00K
Cash3.57M2.35M21.00K3.46M2.43M9.65M11.72M8.49M7.01M1.91M58.64K-1.54M597.54K958.7584.00K455.00K
Total Debt81.00K271.00K1.62M683.00K501.00K338.00K401.00K91.00K97.00K99.58K68.39K1.09M3.48M2.24M3.24M4.65M4.95M
Net Debt-3.49M-2.08M1.60M-2.78M-1.93M-9.31M-11.31M-8.40M-6.92M-1.81M9.75K1.09M1.94M1.64M3.24M4.57M4.50M

Cash Flow

Currency: EUR2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.21M-3.60M-2.71M-2.60M-2.74M-3.44M-5.25M-2.56M-7.60M----3.42M510.00K394.00K
Investing Cash Flow-292.00K-77.00K-62.00K-74.00K-564.00K-296.00K-548.00K-274.00K-47.00K----1.69M-438.00K-244.00K
Financing Cash Flow2.79M2.41M2.54M3.48M2.28M10.94M7.87M-288.00K6.17M---4.50M-160.00K-51.00K
Capital Expenditure219.00K57.00K22.00K55.00K53.00K349.00K395.00K203.00K136.00K000153.00K482.00K252.00K
Free Cash Flow-1.43M-3.66M-2.73M-2.65M-2.79M-3.79M-5.64M-2.76M-7.73M----3.58M28.00K142.00K
Dividends Paid--------7.00K------
FCF to OCF118.04%101.58%100.81%102.12%101.94%110.14%107.53%107.94%101.79%---104.47%5.49%36.04%
Dividend Paid to FCF---------0.09%------

Earnings

Report DateAug 4, 2016Feb 3, 2017May 16, 2017Oct 27, 2017May 9, 2018Jan 8, 2019Dec 30, 2019May 12, 2020Apr 30, 2021Jan 18, 2022Apr 29, 2022Apr 29, 2025Oct 31, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-0.07-0.04-0.14-0.09-0.16-0.18-0.010.000.000.000.000.000.00
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap14.86M
Enterprise Value18.69M
Trailing P/E0.00
Forward P/E7.30
Price / Sales22.48
Price / Book383.61
EPS0.00
Book Value0.00
Revenue (TTM)661.00K
Gross Profit (TTM)442.00K
EBITDA-861.00K
Profit Margin-145.54%
Operating Margin-104.28%
Return on Equity-128.34%
Return on Assets-8.95%
Shares Outstanding1.11B
Shares Float325.70M
Beta0.72
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%